Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease progression.
Alector and GSK (GSK) are co-developing AL101, an investigational monoclonal antibody targeting the sortilin receptor to increase brain progranulin levels, currently being evaluated in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled phase 2 trial led by GSK.
The trial is evaluating two dose levels of AL101, with participants randomized to receive either the drug or a placebo intravenously, and its primary endpoint is disease progression measured by the Clinical Dementia Rating Sum of Boxes, a validated tool for assessing cognitive decline, the biotechnology company said.
Shares of Alector were down 1.9% in recent Thursday trading, while GSK's were up 1%.
Price: 0.96, Change: -0.02, Percent Change: -1.87
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。